Emergent BioSolutions Inc. (EBS) stock

EBSNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3072% below fair value

$5.89−0.15 (-2.48%)

Close on Nov 12, 2026Market cap $302.00MP/E –Yield –

Emergent BioSolutions EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Emergent BioSolutions's EV/EBITDA was 26.5× on Nov 11, 2026, against 4.6× a year earlier. Over the last 5 years it ranged from 4.0× to 112.3×, with a median of 7.5×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	26.5×	+21.5
2025	Dec 31, 2025	4.9×	+0.2
2023	Jan 31, 2023	4.8×	+0.2
2022	Dec 30, 2022	4.5×	−2.9
2021	Dec 31, 2021	7.5×	−9.6
2020	Dec 31, 2020	17.0×	−9.7
2019	Dec 31, 2019	26.8×	+11.3
2018	Dec 31, 2018	15.5×	+3.4
2017	Dec 29, 2017	12.1×	+2.3
2016	Dec 30, 2016	9.8×	−2.2
2015	Dec 31, 2015	12.0×	−4.0
2014	Dec 31, 2014	16.0×	−1.5
2013	Dec 31, 2013	17.5×	+8.4
2012	Dec 31, 2012	9.1×	−8.7
2011	Dec 30, 2011	17.8×	+3.7
2010	Dec 31, 2010	14.0×	–

Where these numbers come from

Parsed from the XBRL in Emergent BioSolutions's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing